OpGen, Inc. (OPGN)
Stock Price:
$2.16 USD
0.00 (0.00%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
Pre-market: $2.18 +0.02 (0.93%) Aug 4, 4:24 AM
Key Info
| Market Cap |
32.55M |
| Revenue (ttm) |
3.10M |
| Net Income (ttm) |
-12.54M |
| Shares Out |
15.46M |
| EPS (ttm) |
-3.75 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$2.16 |
| Previous Close |
$2.16 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
2.18 |
| Day's Range |
2.14 - 2.33 |
| Day's Volume |
1,191,527 |
| 52-Week Range |
0.92 - 12.80 |
More Stats
| Market Cap |
32.55M |
| Enterprise Value |
18.85M |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
15.46M |
| Float |
15.07M |
| EPS (basic) |
-1.86 |
| EPS (diluted) |
-3.75 |
| FCF / Share |
-1.47 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.16M |
| Short Ratio |
0.68 |
| Short % of Float |
7.76% |
| Beta |
-0.54 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
10.52 |
| PB Ratio |
2.48 |
| Revenue |
3.10M |
| Operating Income |
-12.50M |
| Net Income |
-12.54M |
| Free Cash Flow |
-10.86M |
| Net Cash |
13.70M |
| Net Cash / Share |
0.91 |
| Gross Margin |
-105.13% |
| Operating Margin |
-403.95% |
| Profit Margin |
-405.20% |
| FCF Margin |
-350.87% |
| ROA |
-42.10% |
| ROE |
-136.17% |
| ROIC |
-345.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
5.00
Current: $2.16
High
5.00
Target: 5.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 3.50 | 2.95 | 3.21 | 4.03 | 3.16 | 4.13 | 2.41 |
| Revenue Growth | 18.75% | -8.24% | -20.24% | 27.49% | -23.47% | 71.18% | - |
| Gross Profit | 1.87 | 1.10 | 1.08 | 1.74 | 1.61 | 3.17 | 0.59 |
| Operating Income | -12.27 | -13.18 | -15.27 | -19.01 | -15.06 | -5.56 | -10.33 |
| Net Income | -12.45 | -13.37 | -15.42 | -19.17 | -17.35 | -5.67 | -10.13 |
| Shares Outstanding | 1.62 | 0.30 | 0.08 | 0.04 | 0.02 | - | - |
| Earnings Per Share | -7.70 | -44.49 | -196.00 | -551.80 | -1,100.00 | -8,125.00 | -448,045.00 |
| Operating Cash Flow | -11.51 | -11.07 | -14.30 | -17.25 | -14.28 | -5.39 | -7.49 |
| Capital Expenditures | - | -0.14 | -0.28 | -0.12 | -0.19 | -0.04 | -0.11 |
| Free Cash Flow | -11.51 | -11.21 | -14.58 | -17.37 | -14.46 | -5.43 | -7.60 |
| Cash & Equivalents | 5.23 | 4.57 | 1.85 | 4.12 | 7.81 | 0.75 | 1.40 |
| Total Debt | 3.16 | 1.90 | 1.30 | 1.35 | 1.57 | 3.24 | 0.35 |
| Net Cash / Debt | 2.07 | 2.68 | 0.55 | 2.76 | 6.24 | -2.49 | 1.05 |
| Assets | 10.42 | 8.95 | 6.62 | 8.98 | 13.76 | 2.65 | 3.16 |
| Liabilities | 6.13 | 5.64 | 5.22 | 5.82 | 6.27 | 6.16 | 2.99 |
| Book Value | 4.29 | 3.31 | 1.40 | 3.17 | 7.49 | -8.07 | -1.83 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
OpGen, Inc. |
| Country |
United States |
| Employees |
38 |
| CEO |
Oliver Schacht |
Stock Information
| Ticker Symbol |
OPGN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: OPGN |
| IPO Date |
May 5, 2015 |
Description
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect pathogens in positive blood cultures. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.